中风与神经疾病杂志2023，Vol.40Issue(12)：1063-1068,6.DOI:10.19845/j.cnki.zfysjjbzz.2023.0230
A型肉毒毒素与CGRP单克隆抗体药物治疗慢性偏头痛的研究进展
Research advances in calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A for treatment of chronic migraine
赵红如1
作者信息
- 1. 苏州大学附属第一医院神经内科,江苏 苏州 215006
- 折叠
摘要
Abstract
Previous studies have shown that botulinum toxin A can significantly reduce headache frequency and in-tensity and headache-related dysfunction in patients with chronic migraine.Recent evidence has discovered that multiple monoclonal antibodies targeting the calcitonin gene-related peptide(CGRP)pathway can also significantly improve the clinical outcome of chronic migraine.Few studies have compared the preventive effects of the two treatments for chronic mi-graine.This review focuses on the efficacy and safety of botulinum toxin A and monoclonal antibodies against CGRP and CGRP receptor(CGRPr)in the treatment of chronic migraine,as well as the effectiveness of CGRPr monoclonal antibodies following a poor response to botulinum toxin A,aiming to provide a reference for clinical treatment selection.关键词
A型肉毒毒素/降钙素基因相关肽/单克隆抗体药物/慢性偏头痛/预防性治疗Key words
Botulinum toxin A/Calcitonin gene-related peptide/Monoclonal antibody/Chronic migraine/Preventive therapy分类
医药卫生引用本文复制引用
赵红如..A型肉毒毒素与CGRP单克隆抗体药物治疗慢性偏头痛的研究进展[J].中风与神经疾病杂志,2023,40(12):1063-1068,6.
